CO6341558A2 - Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos - Google Patents
Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricosInfo
- Publication number
- CO6341558A2 CO6341558A2 CO10143058A CO10143058A CO6341558A2 CO 6341558 A2 CO6341558 A2 CO 6341558A2 CO 10143058 A CO10143058 A CO 10143058A CO 10143058 A CO10143058 A CO 10143058A CO 6341558 A2 CO6341558 A2 CO 6341558A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- neuropsychiatric disorders
- receiver antagonists
- nmda
- nmda receiver
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12709808P | 2008-05-09 | 2008-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6341558A2 true CO6341558A2 (es) | 2011-11-21 |
Family
ID=41265475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10143058A CO6341558A2 (es) | 2008-05-09 | 2010-11-16 | Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110160223A1 (enExample) |
| EP (1) | EP2296658A4 (enExample) |
| JP (1) | JP2011520815A (enExample) |
| KR (1) | KR20110016891A (enExample) |
| CN (1) | CN102762207A (enExample) |
| AU (1) | AU2009244082A1 (enExample) |
| BR (1) | BRPI0912362A2 (enExample) |
| CA (1) | CA2722776A1 (enExample) |
| CO (1) | CO6341558A2 (enExample) |
| EA (1) | EA020339B1 (enExample) |
| IL (1) | IL208895A0 (enExample) |
| MX (1) | MX2010012186A (enExample) |
| NZ (1) | NZ589764A (enExample) |
| SG (1) | SG195568A1 (enExample) |
| WO (1) | WO2009137843A2 (enExample) |
| ZA (1) | ZA201007958B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102762554A (zh) | 2010-02-16 | 2012-10-31 | 辉瑞大药厂 | 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 |
| CN107936076B (zh) | 2011-09-08 | 2021-10-15 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| WO2013169964A1 (en) * | 2012-05-09 | 2013-11-14 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| WO2013170072A2 (en) * | 2012-05-09 | 2013-11-14 | Neurop, Inc. | Compounds for the treatment of neurological disorders |
| US8974365B2 (en) * | 2012-11-25 | 2015-03-10 | Steven Richard Devore Best | Treatment of thalamocortical dysrhythmia |
| AU2014243773B2 (en) | 2013-03-13 | 2018-12-13 | Sage Therapeutics, Inc. | Neuroactive steroids and methods of use thereof |
| WO2014210456A1 (en) | 2013-06-28 | 2014-12-31 | Emory University | Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses |
| US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3204011A4 (en) * | 2014-10-07 | 2018-06-20 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| US10633336B2 (en) | 2014-12-19 | 2020-04-28 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
| US10752588B2 (en) | 2014-12-19 | 2020-08-25 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
| CA2991214C (en) | 2015-07-06 | 2024-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| JP6882996B2 (ja) | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| US11117924B2 (en) | 2015-07-06 | 2021-09-14 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3383429B1 (en) | 2015-11-30 | 2020-10-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Nmdar antagonists for the treatment of tumor angiogenesis |
| MA44526A (fr) | 2016-04-01 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols et leurs méthodes d'utilisation |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA45598B1 (fr) | 2016-07-07 | 2021-09-30 | Sage Therapeutics Inc | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| RU2019115113A (ru) | 2016-10-18 | 2020-11-24 | Сейдж Терапьютикс, Инк. | Оксистеролы и способы их применения |
| US11111266B2 (en) | 2016-10-18 | 2021-09-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN109803656B (zh) * | 2017-10-09 | 2021-08-31 | 华南农业大学 | 一种抗白色念珠菌的化合物及其制备方法和应用 |
| US11981652B2 (en) | 2018-03-28 | 2024-05-14 | Emory University | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor |
| KR102793535B1 (ko) | 2018-06-27 | 2025-04-11 | 클렉시오 바이오사이언시스 리미티드 | 주요 우울 장애를 치료하는 방법 |
| JP2022504036A (ja) | 2018-10-05 | 2022-01-13 | クレキシオ バイオサイエンシーズ エルティーディー． | 大うつ病性障害を治療するためのエスケタミンの投与計画 |
| US12364672B2 (en) | 2018-10-11 | 2025-07-22 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| CN114539129B (zh) * | 2020-11-18 | 2023-06-09 | 上海中医药大学附属龙华医院 | 烯丙胺类双功能化合物及其用途 |
| JP2024533182A (ja) | 2021-09-02 | 2024-09-12 | エモリー ユニバーシティー | 酸性ｐＨで増強された効力を有するＮ－メチル－Ｄ－アスパラギン酸受容体のＧｌｕＮ２Ｂサブユニット選択的アンタゴニスト |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54130587A (en) * | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| EP0005828B1 (de) * | 1978-06-06 | 1981-03-11 | Hoechst Aktiengesellschaft | Neue substituierte Phenylpiperazinderivate, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung |
| DE2824677A1 (de) * | 1978-06-06 | 1979-12-20 | Hoechst Ag | Neue substituierte phenylpiperazinderivate und verfahren zu deren herstellung |
| JPS55162774A (en) * | 1979-06-06 | 1980-12-18 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| JPS5646812A (en) * | 1979-09-27 | 1981-04-28 | Otsuka Pharmaceut Co Ltd | Central nervous system depressant |
| JPS5649362A (en) * | 1979-09-28 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Thiocarbostyril derivative |
| JPS5649361A (en) * | 1979-09-28 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| JPS579769A (en) * | 1980-06-23 | 1982-01-19 | Otsuka Pharmaceut Co Ltd | 2-benzimidazolinone derivative |
| JPS58203968A (ja) * | 1982-05-21 | 1983-11-28 | Otsuka Pharmaceut Co Ltd | イソカルボスチリル誘導体 |
| DE3442570A1 (de) * | 1984-11-22 | 1986-05-22 | Hoechst Ag, 6230 Frankfurt | Neue substituierte phenylpiperazinderivate, verfahren zu deren herstellung und die verwendung substituierter phenylpiperazinderivate als aggressionshemmer fuer tiere |
| JPS62252783A (ja) * | 1986-02-13 | 1987-11-04 | ワ−ナ−−ランバ−ト・コンパニ− | ベンズ複素環式化合物 |
| GB9005318D0 (en) * | 1990-03-09 | 1990-05-02 | Isis Innovation | Antiarrhythmic agents |
| ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| TW498067B (en) * | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
| CA2681877A1 (en) * | 1997-10-31 | 1999-05-14 | Asubio Pharma Co., Ltd. | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same |
| IL145584A0 (en) * | 2000-10-02 | 2002-06-30 | Pfizer Prod Inc | Nmda nr2b antagonists for treatment |
| WO2002028814A2 (en) * | 2000-10-06 | 2002-04-11 | Regents Of The University Of California | Nmda receptor channel blocker with neuroprotective activity |
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| JP2005506292A (ja) * | 2001-03-08 | 2005-03-03 | エモリー ユニバーシティ | ｐＨに依存するＮＭＤＡレセプターアンタゴニスト |
| DE10248925A1 (de) * | 2002-10-15 | 2004-04-29 | Proteosys Ag | Neue Verbindungen mit dopaminerger und/oder serotoninerger Aktivität |
| WO2004100956A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Method for enhancing cognition using ziprasidone |
| MXPA05012493A (es) * | 2003-05-27 | 2006-05-25 | Forest Laboratories | Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo. |
| HUP0401526A2 (en) * | 2004-07-29 | 2006-04-28 | Richter Gedeon Vegyeszet | Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use |
| AU2005277055B2 (en) * | 2004-08-23 | 2011-03-31 | Emory University | Improved selection of-pH dependent compounds for in vivo therapy |
| JP2009500440A (ja) * | 2005-07-12 | 2009-01-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 性欲障害治療用医薬組成物 |
| TWI329641B (en) * | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
| US7935706B2 (en) * | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| WO2008020306A2 (en) * | 2006-08-18 | 2008-02-21 | Pfizer Products Inc. | Isoindole derivatives |
| CN101815518B (zh) * | 2007-06-29 | 2013-01-09 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
-
2009
- 2009-05-11 JP JP2011508724A patent/JP2011520815A/ja active Pending
- 2009-05-11 CN CN2009801184245A patent/CN102762207A/zh active Pending
- 2009-05-11 KR KR1020107025739A patent/KR20110016891A/ko not_active Ceased
- 2009-05-11 MX MX2010012186A patent/MX2010012186A/es not_active Application Discontinuation
- 2009-05-11 EA EA201071291A patent/EA020339B1/ru not_active IP Right Cessation
- 2009-05-11 CA CA2722776A patent/CA2722776A1/en not_active Abandoned
- 2009-05-11 SG SG2013077359A patent/SG195568A1/en unknown
- 2009-05-11 WO PCT/US2009/043502 patent/WO2009137843A2/en not_active Ceased
- 2009-05-11 NZ NZ589764A patent/NZ589764A/xx not_active IP Right Cessation
- 2009-05-11 BR BRPI0912362A patent/BRPI0912362A2/pt not_active IP Right Cessation
- 2009-05-11 EP EP09743829.5A patent/EP2296658A4/en not_active Withdrawn
- 2009-05-11 AU AU2009244082A patent/AU2009244082A1/en not_active Abandoned
-
2010
- 2010-10-24 IL IL208895A patent/IL208895A0/en unknown
- 2010-11-02 US US12/938,138 patent/US20110160223A1/en not_active Abandoned
- 2010-11-05 ZA ZA2010/07958A patent/ZA201007958B/en unknown
- 2010-11-16 CO CO10143058A patent/CO6341558A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20110160223A1 (en) | 2011-06-30 |
| CN102762207A (zh) | 2012-10-31 |
| MX2010012186A (es) | 2011-02-22 |
| EP2296658A4 (en) | 2014-01-15 |
| WO2009137843A9 (en) | 2010-03-11 |
| WO2009137843A2 (en) | 2009-11-12 |
| EA020339B1 (ru) | 2014-10-30 |
| BRPI0912362A2 (pt) | 2015-10-06 |
| EA201071291A3 (ru) | 2014-02-28 |
| IL208895A0 (en) | 2011-01-31 |
| KR20110016891A (ko) | 2011-02-18 |
| JP2011520815A (ja) | 2011-07-21 |
| CA2722776A1 (en) | 2009-11-12 |
| ZA201007958B (en) | 2011-07-27 |
| SG195568A1 (en) | 2013-12-30 |
| AU2009244082A1 (en) | 2009-11-12 |
| EP2296658A2 (en) | 2011-03-23 |
| EA201071291A2 (ru) | 2011-04-29 |
| NZ589764A (en) | 2012-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6341558A2 (es) | Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos | |
| CU24187B1 (es) | Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis | |
| DOP2015000157A (es) | Lactamas fusionadas de arilo y heteroarilo | |
| UY32574A (es) | Antagonistas del receptor cxcr3 | |
| UY34530A (es) | Antagonistas del receptor de vanilloides de potencial transitorio 1 (trpv1) | |
| CO6480975A2 (es) | Mimetico de smac | |
| CL2017001984A1 (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014) | |
| UY34960A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| PE20160841A1 (es) | Macrociclos como inhibidores del factor de coagulacion (fxia) | |
| DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| CR20150296A (es) | Novedosos derivados de bencimidazol como antagonistas de ep4 | |
| CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| UY34959A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| DOP2013000267A (es) | Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3 | |
| MX2016009230A (es) | Macrociclicos con grupos p2'heterociclicos como inhibidores del factor xia. | |
| CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| CR20140397A (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks | |
| CO6410295A2 (es) | Derivados de indol como antagonistas del receptor crth2 | |
| CU20140048A7 (es) | Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos | |
| CO6361994A2 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
| MX2015013711A (es) | Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selecticos de receptor de nk-3, composicion farmaceutica y metodos para su uso en trastornos mediados por el receptor de nk-3. | |
| UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
| PA8842501A1 (es) | Compuestos novedosos como ligandos de receptores de canabinoides | |
| DOP2009000287A (es) | Oxazolidinonas sustituidas y su uso | |
| CU24263B1 (es) | Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |